Overview
Investment Stage
Series C
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 28, 2026 | Lighthouse Pharmaceuticals: $12 Million Raised For Targeting Alzheimer’s Disease | Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative and inflammatory diseases, has closed a $12 million Series A financing round led by Double Point Ventures, with... |
| Jan 20, 2025 | Umoja Biopharma's $100 Million Leap: A New Era for In Vivo CAR T Cell Therapies | Umoja Biopharma is on the rise. The Seattle-based company has just secured $100 million in Series C financing. This is not just a number; it’s a statement. It signals a bold step forward in the world of biotechnology. The funding round was ... |
| Jan 20, 2025 | Umoja Biopharma Raises $100M in Series C Financing | Umoja Biopharma, a Seattle, WA-based clinical-stage company which specializes in vivo cell therapies, raised $100M Series C financing. The round was led by Double Point Ventures and DCVC Bio, with participation from new and existing investo... |
| Sep 18, 2024 | Immunos Therapeutics raises USD11 million | ImmunOs’ lead program IOS-1002 is currently tested in a Phase Ia dose escalation clinical trial as a monotherapy and in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). IOS-1002 is a novel, multifunctional immunotherapy a... |
| Jun 15, 2024 | Eko Health: $41 Million Closed To Scale AI-Based Heart And Lung Disease Detection Technology | Eko Health, a company that is applying artificial intelligence for early detection of heart and lung diseases, announced it has raised $41 million in Series D financing. With participation from ARTIS Ventures, Highland Capital Partners, NTT... |
| Apr 25, 2024 | Cerevance Secures $47M to Drive Innovation in CNS Therapeutics | Cerevance, a Boston-based company specializing in precision treatments for central nervous system (CNS) disorders, recently closed a $47 million Series B-1 Extension financing round. The funding, led by Agent Capital, Bioluminescence Ventur... |
| Apr 25, 2024 | Cerevance Raises $47M in Series B-1 Extension | Cerevance, a Boston, MA-based company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, raised $47M in Series B-1 Extension. The round was led by Agent Capital, Bioluminescence Ventures, and Doubl... |
Reviews 0
FAQ about Double Point Ventures
How many startups has Double Point Ventures invested in?
Double Point Ventures has 1 portfolio company on Parsers VC.
What has the press written about Double Point Ventures?
Parsers VC has collected 8 articles mentioning Double Point Ventures, among them “Lighthouse Pharmaceuticals: $12 Million Raised For Targeting Alzheimer’s Disease” (Apr 28, 2026) and “Umoja Biopharma's $100 Million Leap: A New Era for In Vivo CAR T Cell Therapies” (Jan 20, 2025).
Is Double Point Ventures still active?
Yes, Double Point Ventures is active; its latest activity on Parsers VC dates from May 12, 2026.